Inpharma 1289 - 26 May 2001 Eptifibatide has long-term benefits post-PCI Eptifibatide improves long-term outcomes in patients with coronary artery disease (CAD) undergoing nonurgent coronary stent implantation, report investigators from the ESPRIT * trial. The short-term outcomes of this study have already been reported. ** In this multinational study, 2064 such patients were randomised to receive a bolus dose of eptifibatide [‘Integrilin’] 180 µg/kg, followed immediately by a 2 µg/kg/min infusion (continued for 18–24 hours, until hospital discharge), then a second bolus 10 minutes later (n = 1040) or placebo, commencing immediately prior to percutaneous coronary intervention (PCI; the majority of patients received stents). † 1965 patients were evaluable for efficacy at 6 months. At 6 months’ follow-up, the composite endpoint of death or myocardial infarction (MI) had occurred in significantly fewer eptifibatide, compared with placebo, recipients (7.5 vs 11.5% of patients). Similarly, the combined incidence of death, MI, or target vessel revascularisation at 6 months had occurred in significantly fewer eptifibatide, compared with placebo, recipients (14.2 vs 18.3% of patients). No significant difference in 6-month mortality was seen between the eptifibatide and placebo groups (0.8 vs 1.4%). The researchers conclude that their data ‘argue strongly that all patients undergoing PCI should be considered for treatment with an inhibitor of the platelet Gp [glycoprotein] IIb/IIIa integrin’. * Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrelin Therapy ** see Inpharma 1231: 15–16, 1 Apr 2000; 800763453 and Inpharma 1269: 21, 6 Jan 2001; 800852162 † The ESPRIT trial was funded by COR Therapeutics, US, and Schering- Plough Research Institute, US. O’Shea JC, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT Trial: a randomized controlled trial. JAMA: the Journal of the American Medical Association 285: 2468-2473, 16 May 2001 800861326 1 Inpharma 26 May 2001 No. 1289 1173-8324/10/1289-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Eptifibatide has long-term benefits post-PCI

Download PDF Report

View
212
Download
0

Embed Size (px)

Citation preview

Inpharma 1289 - 26 May 2001

Eptifibatide has long-term benefitspost-PCI

Eptifibatide improves long-term outcomes in patientswith coronary artery disease (CAD) undergoingnonurgent coronary stent implantation, reportinvestigators from the ESPRIT* trial. The short-termoutcomes of this study have already been reported.**

In this multinational study, 2064 such patients wererandomised to receive a bolus dose of eptifibatide[‘Integrilin’] 180 µg/kg, followed immediately by a 2µg/kg/min infusion (continued for 18–24 hours, untilhospital discharge), then a second bolus 10 minuteslater (n = 1040) or placebo, commencing immediatelyprior to percutaneous coronary intervention (PCI; themajority of patients received stents).† 1965 patientswere evaluable for efficacy at 6 months.

At 6 months’ follow-up, the composite endpoint ofdeath or myocardial infarction (MI) had occurred insignificantly fewer eptifibatide, compared with placebo,recipients (7.5 vs 11.5% of patients). Similarly, thecombined incidence of death, MI, or target vesselrevascularisation at 6 months had occurred insignificantly fewer eptifibatide, compared with placebo,recipients (14.2 vs 18.3% of patients).

No significant difference in 6-month mortality wasseen between the eptifibatide and placebo groups (0.8vs 1.4%).

The researchers conclude that their data ‘arguestrongly that all patients undergoing PCI should beconsidered for treatment with an inhibitor of the plateletGp [glycoprotein] IIb/IIIa integrin’.* Enhanced Suppression of the Platelet IIb/IIIa Receptor with IntegrelinTherapy** see Inpharma 1231: 15–16, 1 Apr 2000; 800763453 and Inpharma1269: 21, 6 Jan 2001; 800852162† The ESPRIT trial was funded by COR Therapeutics, US, and Schering-Plough Research Institute, US.

O’Shea JC, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatidein coronary stent intervention: the ESPRIT Trial: a randomized controlled trial.JAMA: the Journal of the American Medical Association 285: 2468-2473, 16 May2001 800861326